Company Overview
Company Overview
Collaborative Innovation
Hua Medicine is an innovative drug development and commercialization company with headquarters in Shanghai, China, and divisions in the United States and Hong Kong, China. Hua Medicine focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care.
Hua Medicine adheres to the tenet of "For Patients, Global Innovation, Effective Medicines" by integrating global pharmaceutical research and development resources, joint innovation and mutual benefit operation model, thereby achieving the goal of the healthy development of humans.
The Hua Medicine's cornerstone product, HuaTangNing (dorzagliatin tablets, HMS5552), targeting the glucose sensor known as glucokinase. This medication aims to restore glucose sensitivity in individuals with T2D and stabilize the imbalanced blood glucose levels in patients. Notably, the National Medical Products Administration (NMPA) of China granted approval for HuaTangNing on September 30th, 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. There is no need for dose adjustment in patients diagnosed with chronic kidney disease (CKD). It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine has established a collaborative alliance with Bayer, a renowned international pharmaceutical company, in order to facilitate the commercialization of HuaTangNing within the Chinese market. This collaborative effort is anticipated to yield favorable effects for persons afflicted with diabetes, as well as their respective families.
Dorzagliatin is an allosteric glucokinase (GK) full activator that acts on glucokinase targets in pancreatic islets, intestinal endocrine cells, liver and other glucose storage and output organs. It improves impaired glucose-stimulated insulin secretion and GLP-1 secretion in Type 2 diabetes patients, thereby improving β-cell function and reducing insulin resistance. Consequently, it restores the physiological regulation of blood glucose homeostasis in patients with Type 2 diabetes.
Clinical trials have demonstrated that HuaTangNing can restore blood glucose homeostasis in patients with Type 2 Diabetes (T2D) patients by repairing the impaired glucokinase and restoring the glucose sensing function. After the SEED study, the potential of dorzagliatin in diabetes remission is continued to be explored. during the research period, dorzagliatin treatment leads to drug-free diabetes remission. The remission probability was 65.2% at week 52.
In the future, Hua Medicine aspires to accomplish a development from 1 to 10 in three dimensions, including the launch of new products, the exploration of new markets, and the discovery of new disease fields, and to actualize its vision of "China leading pharmaceutical innovation."
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
